The appointment expands the current Board of Directors' role to oversee Psilera's clinical development strategy for its next-generation neuroplastogens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback